Sign in

CIK 0001737287

  • Non-accelerated filer
  • Smaller reporting company

Allogene Therapeutics, Inc.

Sign in to watch
Ticker
ALLO
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Entity type
Operating
EIN
823562771
Phone
+1 650-457-2700
Business address
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
  1. 4 Grant or award EVP of R&D acquired 148,035 shares (grant or award)
  2. 4 Grant or award Director acquired 1,282,976 shares (grant or award)
  3. 4 Grant or award President and CEO acquired 1,924,464 shares (grant or award)
  4. 4 Shares withheld for taxes President and CEO gave up 22,340 shares (to pay taxes)
  5. 4 Shares withheld for taxes Chief Financial Officer gave up 35,879 shares (to pay taxes)
  6. 4 Shares withheld for taxes Chief Technical Officer gave up 8,351 shares (to pay taxes)
  7. 4 Shares withheld for taxes General Counsel gave up 23,628 shares (to pay taxes)
  8. 4 Open-market sale General Counsel sold 3,000 shares at $6.85 ($20,550)
  9. 4 Grant or award EVP of R&D acquired 251,908 shares (grant or award)
  10. 4 Open-market sale General Counsel sold 3,000 shares at $7.04 ($21,120)
  11. 3 Insider Initial Statement of Ownership
  12. 4 Open-market sale General Counsel sold 5,602 shares at $7.53 ($42,186)
  13. 4 Shares withheld for taxes EVP of R&D gave up 8,464 shares (to pay taxes)
  14. 4 Shares withheld for taxes EVP of R&D gave up 8,968 shares (to pay taxes)
  15. 4 Open-market sale Director sold 15,000 shares at an average $16.75 ($251,250)
  16. 4 Open-market sale Director sold 15,000 shares at an average $16.75 ($251,250)
  17. 4 Open-market sale EVP of R&D and CMO sold 2,000 shares at $11.97 ($23,940)
  18. 4 Grant or award Director acquired 35,328 shares (grant or award)
  19. 3 Insider Initial Statement of Ownership
  20. 4 Open-market sale EVP of R&D and CMO sold 2,000 shares at $11.44 ($22,880)

Page 6 of 14 · 275 filings